Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer-Reference-Cited by-同舟云学术

Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer

Published:2022-08 Issue:4 Volume:44 Page:520-526
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Molenaar-Kuijsten Laura,Verheijen Remy B.,Jacobs Bart A. W.,Thijssen Bas,Rosing Hilde,Dorlo Thomas P. C.,Beijnen Jos H.,Steeghs Neeltje,Huitema Alwin D. R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference12 articles.

1. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology;Ravaud;Eur J Cancer,2014

2. Pharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trial;Verheijen;Clin Pharmacokinet.,2018

3. Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer;de Wit;Cancer Chemother Pharmacol.,2016

4. A semi-physiological population model to quantify the effect of hematocrit on everolimus pharmacokinetics and pharmacodynamics in cancer patients;van Erp;Clin Pharmacokinet.,2016

5. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients;Ter Heine;Br J Clin Pharmaco,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review;Pharmaceutics;2023-01-10